Literature DB >> 15860913

Biophysical and physiological properties of porcine surfactant enriched with polymyxin B.

A Calkovska1, M Some, B Linderholm, J Johansson, T Curstedt, B Robertson.   

Abstract

OBJECTIVE: We examined whether the biophysical and physiological properties of Curosurf were improved by the cyclic amphipathic decapeptide polymyxin B (PxB).
METHODS: Curosurf was diluted to 1-5 mg/ml with PxB added at 1, 2 or 3% (w/w). Albumin was added at 40 mg/ml. Minimum surface tension (gammamin) during surface compression was determined for each mixture with pulsating bubble. Immature newborn rabbits were treated with 2.5 ml/kg of Curosurf 80 mg/ml, or Curosurf 32 mg/ml with or without 2% PxB and ventilated for up to 5 h.
RESULTS: At surfactant concentration 2 mg/ml, gammamin was high (17 +/- 8.9 mN/m) but remained low (2.7 +/- 0.8 mN/m) when PxB was added. Albumin inactivated Curosurf at both 2 and 3.5 mg/ml; this inactivation was prevented by 2% PxB. Treatment of newborn rabbits with Curosurf 80 mg/kg + 2% PxB significantly decreased incidence of pneumothorax in comparison with controls but had no significant effect on lung-thorax compliance or alveolar expansion.
CONCLUSION: Addition of 2% PxB improves surface activity of Curosurf at low concentration, increases its resistance to inactivation by albumin, and reduces the incidence of pneumothorax in immature newborn rabbits undergoing prolonged ventilation. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860913     DOI: 10.1159/000085524

Source DB:  PubMed          Journal:  Biol Neonate        ISSN: 0006-3126


  8 in total

1.  Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome.

Authors:  Andrea Calkovska; Daniela Mokra; Anna Drgova; Ivan Zila; Kamil Javorka
Journal:  Eur J Pediatr       Date:  2007-10-19       Impact factor: 3.183

Review 2.  Non-Reflex Defense Mechanisms of Upper Airway Mucosa: Possible Clinical Application.

Authors:  H Pedan; V Janosova; A Hajtman; V Calkovsky
Journal:  Physiol Res       Date:  2020-03-27       Impact factor: 1.881

3.  Pulmonary surfactant preserves viability of alveolar type II cells exposed to polymyxin B in vitro.

Authors:  Guido Stichtenoth; Egbert Herting; Mario Rüdiger; Andreas Wemhöner
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

4.  Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin.

Authors:  Yuliannis Lugones; Odalys Blanco; Elena López-Rodríguez; Mercedes Echaide; Antonio Cruz; Jesús Pérez-Gil
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

5.  The Perturbation of Pulmonary Surfactant by Bacterial Lipopolysaccharide and Its Reversal by Polymyxin B: Function and Structure.

Authors:  Maros Kolomaznik; Gilda Liskayova; Nina Kanjakova; Lukas Hubcik; Daniela Uhrikova; Andrea Calkovska
Journal:  Int J Mol Sci       Date:  2018-07-05       Impact factor: 5.923

6.  Restoration of surfactant activity by polymyxin B in lipopolysaccharide-potentiated injury of immature rabbit lungs.

Authors:  Andrea Calkovska; Marie Haegerstrand-Björkman; Tore Curstedt
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

Review 7.  What's new in surfactant? A clinical view on recent developments in neonatology and paediatrics.

Authors:  Jasper V Been; Luc J I Zimmermann
Journal:  Eur J Pediatr       Date:  2007-05-22       Impact factor: 3.183

8.  The Effect of Modified Porcine Surfactant Alone or in Combination with Polymyxin B on Lung Homeostasis in LPS-Challenged and Mechanically Ventilated Adult Rats.

Authors:  Maros Kolomaznik; Jana Kopincova; Zuzana Nova; Juliana Topercerova; Ivan Zila; Pavol Mikolka; Petra Kosutova; Katarina Matasova; Henrieta Skovierova; Marian Grendar; Daniela Mokra; Andrea Calkovska
Journal:  Molecules       Date:  2020-09-23       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.